SCHEMBL3087045

SCHEMBL3087045

NC(=O)c1ccnnc1N1CCCCC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.49
HTT P42858 1/20 0.45
CDC7 O00311 2/20 0.43
CDK9 P50750 1/20 0.43
KDM4E B2RXH2 3/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
HSD17B10 Q99714 2/20 0.43
MAPT P10636 1/20 0.43
THRB P10828 1/20 0.43
ALOX15 P16050 1/20 0.43
GFER P55789 1/20 0.43
YWHAG P61981 1/20 0.43
HPGD P15428 2/20 0.41
ALDH1A1 P00352 4/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
ROCK2 O75116 1/20 0.40
MAP4K4 O95819 1/20 0.40
CDK2 P24941 1/20 0.40
GSK3B P49841 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28189129 0.77 KMT2A (0.60) NPC1HTTMEN1KMT2AHSD17B10
SCHEMBL883905 0.75 KMT2A (0.58) NPC1KDM4EMEN1KMT2AHSD17B10
SCHEMBL7242650 0.74 NPC1 (0.49) NPC1HTTCDC7CDK9KDM4E
SCHEMBL3084564 0.74 HPGD (0.47) NPC1HTTKDM4EMEN1KMT2A
SCHEMBL4787751 0.74 NPC1 (0.45) NPC1HTTCDC7CDK9KDM4E
SCHEMBL20998571 0.72 NPC1 (0.46) NPC1HTTCDC7CDK9KDM4E
SCHEMBL8918616 0.70 SMN1; SMN2 (0.49) NPC1KDM4EMEN1KMT2AHSD17B10
SCHEMBL3083678 0.69 CYP1A2 (0.62) HTTKDM4EMEN1KMT2AMAPT
SCHEMBL4309528 0.69 CDC7 (0.62) NPC1HTTCDC7CDK9KDM4E
SCHEMBL4727172 0.69 ADRB2 (0.38) ALDH1A1CLK4TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7790724-B2 c-fms kinase inhibitors JANSSEN PHARMACEUTICA N.V. (BE) 2010-09-07 US claimed
EP-2016057-A1 C-FMS KINASE INHIBITORS JANSSEN PHARMACEUTICA N.V. (BE) 2009-01-21 EP claimed
WO-2007123516-A1 C-FMS KINASE INHIBITORS JANSSEN PHARMACEUTICA, N.V. (BE) 2007-11-01 WO claimed
US-20060258666-A1 c-fms kinase inhibitors JANSSEN PHARMACEUTICA N.V. (BE) 2006-11-16 US claimed
US-7790724-B2 c-fms kinase inhibitors JANSSEN PHARMACEUTICA N.V. (BE) 2010-09-07 US disclosed
EP-2016057-A1 C-FMS KINASE INHIBITORS JANSSEN PHARMACEUTICA N.V. (BE) 2009-01-21 EP disclosed
WO-2007123516-A1 C-FMS KINASE INHIBITORS JANSSEN PHARMACEUTICA, N.V. (BE) 2007-11-01 WO disclosed
US-20060258666-A1 c-fms kinase inhibitors JANSSEN PHARMACEUTICA N.V. (BE) 2006-11-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060258666-A1 c-fms kinase inhibitors FLT3, FES, FER NPC1 4368/4885HTT 2335/4885CDC7 294/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.